Abstract
In this issue of Blood, Mahe vas et al demonstrate that an immunomodulatory drug or a proteasome inhibitor partnered with dexamethasone can lead to a clinically meaningful improvement in severe cases of scleromyxedema that are refractory to high-dose IV immunoglobulin (IVIG).1 2020 by The American Society of Hematology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1074-1076 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 135 |
| Issue number | 14 |
| DOIs | |
| State | Published - Apr 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology